Fig. 1
Progression-free survival time in the two groups mPFS: D-TACE + Donafenib + Tislelizumab group, 8.7 months (95%CI 6.9–9.1 months); D-TACE + Sorafenib group, 5.7 months (95%CI 4.2–5.8 months).
Fig. 1 | Scientific Reports
Progression-free survival time in the two groups mPFS: D-TACE + Donafenib + Tislelizumab group, 8.7 months (95%CI 6.9–9.1 months); D-TACE + Sorafenib group, 5.7 months (95%CI 4.2–5.8 months).
